General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
In combination with ibrutinib, is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
Last updated March 29, 2026
Status:
Concluded without agreement
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
Growth hormone deficiency
Last updated March 27, 2026
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
In combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are not candidates for autologous stem cell transplant.
Last updated March 25, 2026
Status:
Active negotiation
Manufacturer:
Merck Canada Inc.
Indication:
For the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
Last updated March 20, 2026
Status:
Active negotiation
Manufacturer:
Biogen Canada Inc.
Indication:
Amyotrophic Lateral Sclerosis (ALS)
Last updated March 18, 2026
Status:
Active negotiation
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
Chronic hepatitis delta virus (HDV) infection
Last updated March 16, 2026
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
In combination with gemcitabine and oxaliplatin for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are not candidates for autologous stem cell transplant (ASCT).
Last updated March 16, 2026
Status:
Concluded with an LOI
Manufacturer:
Apotex Inc.
Indication:
Multiple Indications
Last updated March 9, 2026
Status:
Concluded without agreement
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Paroxysmal nocturnal hemoglobinuria (PNH)
Last updated March 6, 2026
Status:
Active negotiation
Manufacturer:
Sanofi Genzyme Canada
Indication:
In combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).
Last updated February 20, 2026